Psoriasis affects patient's quality of life more seriously in female than in male in Japan

Tokai Journal of Experimental and Clinical Medicine

Volumn 37, Issue 3, 2012, Pages 84-88

  Mabuchi, Tomotaka ^a   Yamaoka, Hanako ^a   Kojima, Tomoko ^a   Ikoma, Norihiro ^a   Akasaka, Emiko ^a   Ozawa, Akira ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dermatology; DLQI; Psoriasis; Quality of life

Indexed keywords

ADULT; ARTICLE; CORRELATIONAL STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ASSESSMENT; PSORIASIS; QUALITY OF LIFE; SEX DIFFERENCE; VISUAL ANALOG SCALE;

ADULT; AGED; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 84867424040     PISSN: 03850005     EISSN: 21852243     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
2. Ashcroft DM, Li Wan Po A, Williams HC, Grifths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23: 391-398.
3. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
5. Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y, et al. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006; 4: 46.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
7. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
8. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10: 644-653.
9. Finlay AY, Kelly SE. Psoriasis--an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
10. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically signicant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
11. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A, The Japanese Ustekinumab Study Group. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol 2012.
12. Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Iniximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of iniximab. J Dermatol 2012; 39: 253-259.
13. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388-394.
14. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005; 152: 1256-1262.